Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07169136 · ClinicalTrials.gov registry record

Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

A clinical trial of Obesity (Disorder) and Polycystic Ovarian Syndrome in Adolescent Females, sponsored by Nemours Children's Clinic.

Recruiting
Registry status
20
Enrollment target
1
Study location

NCT07169136: Recruiting study of Obesity (Disorder) and Polycystic Ovarian Syndrome in Adolescent Females, sponsored by Nemours Children's Clinic.

NCT07169136 is a study of Obesity (Disorder) and Polycystic Ovarian Syndrome in Adolescent Females that is actively recruiting participants, run by Nemours Children's Clinic. The registered enrollment target is 20 participants, below the 110-participant average among 5 other Obesity (Disorder) trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07169136, a study of Obesity (Disorder) and Polycystic Ovarian Syndrome in Adolescent Females, is actively recruiting participants, sponsored by Nemours Children's Clinic.

RECRUITING
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and/or ethnic minorities. Normal puberty onset and progression is dependent on normal hypothalamic-pituitary-gonadal (HPG) axis which is affected by whole body metabolism. Gonadotropin-releasing hormone (GnRH) and gonadotropins, LH and FSH, are released in a pulsatile manner for appropriate sex steroids production and gonadal function. Proper pulsatility in the GnRH system is disrupted by a significant change in energy balance such as in obesity. Polycystic Ovary Syndrome (PCOS) is the most common neuroendocrine dysfunction in women of reproductive age. Glucagon-like peptide-1 (GL-1), a peptide hormone secreted by the intestinal enteroendocrine L-cells following glucose and fat intake, stimulates insulin release by the pancreas in response to glucose, decreases gastric emptying and inhibits glucagon secretion. GLP-1 receptors are present in the hypothalamic nuclei and pituitary gland; and it is thought that GLP-1 may directly stimulate GnRH secretion and partially regulate reproduction. In animal studies, GLP-1 was found to stimulate GnRH secretion, to regulate kisspeptin (Kiss-1) mRNA and GnRH mRAN expression. GLP-1 receptor agonists are FDA-approved to treat adults and adolescents with obesity. Although the impact of GLP-1 receptor agonists in reproductive health has been investigated in preclinical trials, and in men with obesity and functional hypogonadism, no studies to date have investigated the impact of GLP-1 receptor agonists in female neuroendocrine function, particularly in youth. The goal of this proposal is to gather critical preliminary data to investigate, in a group of obese adolescent females with PCOS, the impact of GLP-1 agonist administration in addition to lifestyle modifications on the neuroendocrine rhythms - LH frequency and amplitude (principal); body

Primary Outcome

LH will be obtained every 20 minutes overnight. LH will be measured using a chemiluminescence assay. Pulse frequency will be calculated using mathematical deconvolution analysis.

Interventions

  • DRUG GLP-1 Receptor Agonists

Study Locations (1)

Florida

  • Nemours Children's Clinic - Jacksonville

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-09-11
Est. Completion 2026-12
Nemours Children's Clinic

108 total trials

What NCT07169136 shows while recruiting

NCT07169136 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 110-participant average among 5 other Obesity (Disorder) trials with a reported enrollment target (82% lower).

The record links to 2 conditions, with Obesity (Disorder) appearing as the primary indexed condition, and to 1 intervention - of which GLP-1 Receptor Agonists is the first listed.

NCT07169136 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT07169136 about?

NCT07169136 is a clinical study titled "Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)". The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and/or ethnic minorities. Normal puberty onset and progression is dependent on normal hypothalamic-pituita...

What is the current status of trial NCT07169136?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2025-09-11. Estimated completion is 2026-12.

What conditions does trial NCT07169136 study?

This clinical trial studies the following conditions: Obesity (Disorder), Polycystic Ovarian Syndrome in Adolescent Females.

What interventions are being tested in trial NCT07169136?

The interventions under investigation include: GLP-1 Receptor Agonists (DRUG).

Who is sponsoring clinical trial NCT07169136?

This trial is sponsored by Nemours Children's Clinic, which has 108 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07169136 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity (Disorder)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07169136, the US trial registry maintained by the National Library of Medicine. NCT07169136 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.